FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new ...
Zoe Lazarra, Claudia Ciciliano, and Shankar Narayanan assess where artificial intelligence (AI) is already proving its value ...
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
Experts consider what happens when artificial intelligence (A) tools multiply faster than organizations can connect them.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward ...
A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.
AstraZeneca has entered a deal to acquire Omniose, following a three-year exclusive research collaboration between the two organizations that both sides described as productive. C ...
FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.
Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.
Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...
Single-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment ...
Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results